Should I start a GLP-1?
Risks, benefits, Foundayo and other orals, why dual agonists often win, and why maintenance dosing matters after weight loss.
Read the briefing
A weekly note on preventive medicine, metabolism, and the distance between what the evidence shows and what a patient is left to do with it.
Read the latest briefingOne result becomes a rule. One association becomes a cause. One person’s response becomes everybody’s answer.
The exam room is less cooperative.
Useful evidence, its limits, and the decision hiding underneath the test.
Risks, benefits, Foundayo and other orals, why dual agonists often win, and why maintenance dosing matters after weight loss.
Read the briefingBoard certified internist. Former academic hospitalist and assistant professor. Now practicing outpatient medicine, where prevention has to survive short appointments, fragmented records, and the rest of a person’s life.
HealthyLifeMD follows the questions that remain after the chart closes: metabolic risk, advanced cardiovascular markers, strength, medication burden, and where clinical certainty gets ahead of the science.